Invasive group A streptococcal infection

The condition is caused by Group A Streptococcus, which comprises gram-positive cocci arranged in chains that demonstrate complete hemolysis on blood agar media ^[3]. Within the Lancefield classification system, these organisms are designated as group A β-hemolytic Streptococcus ^[3]. Their invasive potential is driven by a diverse array of bacterial virulence factors ^[1].

Initial manifestations frequently include flu-like symptoms such as high fever, often accompanied by upper respiratory or gastrointestinal complaints ^[4]. Disease progression can be rapid, with approximately ten percent of cases developing streptococcal toxic shock syndrome due to superantigen toxin production ^[1]. In pregnant individuals, presentation may feature intense uterine contractions that mimic placental abruption ^[4].

Current incidence estimates in industrialized regions range from three to four cases per 100,000 population, reflecting its uncommon but severe nature ^[1]. Historical data document periodic resurgences beginning in the 1980s, with recent high-income nations experiencing increased burdens during the late COVID-19 pandemic period ^[2]. These temporal shifts appear associated with altered circulation patterns, co-circulating respiratory viruses, and emerging hypervirulent bacterial lineages ^[2].

The primary route of spread involves direct person-to-person contact through respiratory droplets ^[3]. Transmission can also occur via direct contact with infected bodily fluids, including saliva, wound exudate, or nasal secretions ^[3]. While environmental or foodborne pathways are theoretically possible, they represent less frequent mechanisms, and no animal reservoir has been identified for human transmission ^[3].

Public health measures emphasize minimizing exposure and interrupting transmission chains through strict adherence to infection-control protocols ^[3]. Management strategies prioritize prompt antimicrobial therapy for active cases and consider prophylactic antibiotics in specific clinical scenarios ^[3]. Currently, immunization remains unavailable for preventing group A streptococcal disease ^[3].

1. 1Steer AC et al. Invasive group a streptococcal disease: epidemiology, pathogenesis and management. Drugs. 2012 Jun 18. PMID: 22686614. doi: 10.2165/11634180-000000000-00000.PubMed: https://pubmed.ncbi.nlm.nih.gov/22686614/
2. 2Flamant A et al. Invasive group A streptococcal infections: lessons learned from the 2022-23 upsurge. Lancet Infect Dis. 2026 Feb. PMID: 40651487. doi: 10.1016/S1473-3099(25)00343-3.PubMed: https://pubmed.ncbi.nlm.nih.gov/40651487/
3. 3US Centers for Disease Control and Prevention. Clinical Considerations for Group A Streptococcus | Group A Strep | CDC [Internet]. cited 4 Sept 2026.Available from: https://www.cdc.gov/group-a-strep/hcp/clinical-guidance/index.html
4. 4Yamada T et al. Invasive group A streptococcal infection in pregnancy. J Infect. 2010 Jun. PMID: 20359498. doi: 10.1016/j.jinf.2010.03.011.PubMed: https://pubmed.ncbi.nlm.nih.gov/20359498/